Asha Therapeutics has revealed its selection of an innovative internal-binding compound, designated ASHA-624, intended as a treatment agent to alter the progression of Amyotrophic Lateral Sclerosis.

The U.S. authorities have endorsed the review of a licensing request for Datopotamab Deruxtecan.

IASO Bio has disclosed official authorization from the China National Medical Products Administration for the clinical trial application of Equecabtagene Autoleucel.

Bristol Myers Squibb Reveals Key Outcomes from KRYSTAL-12 Study on KRAZATI (adagrasib) Demonstrating Main Goal of Halting Disease Progress in Advanced KRASG12C-Altered Non-Small Cell Lung Cancer.

The EU Commission has approved the use of Merck's drug KEYTRUDA® (pembrolizumab) in combination with chemotherapy as a first treatment.

Encouraging initial human trial Phase 1B results for VRON-0200, an innovative checkpoint modifier for Chronic Hepatitis B, were showcased as a late-breaking entry at the APASL 2024 Global Liver Conference.

Biond Biologics reveals at the 2024 AACR Annual Meeting, the introduction of their pioneering anti-ILT3 antibody, BND-35, designed to transform the tumor microenvironment.

REGENXBIO Reveals Study in The Lancet on Initial Trial for Single-Dose Gene Therapy ABBV-RGX-314 Targeting Wet Age-Related Macular Degeneration.

Neurocrine Biosciences Launches Early-Stage Trial for New VMAT2 Blocker, NBI-1065890, in Adult Participants.

Gilead and Xilio have entered into a unique licensing deal dedicated to the development of an oncology-targeted IL-12 initiative.

Ironwood Pharma Reveals Encouraging Outcomes in Phase 2 STARGAZE Study for Apraglutide Treating GI aGVHD Unresponsive to Steroids.

Avalo secures IL-1β monoclonal antibody and reveals plans for a private investment round potentially reaching $185M.